Elagolix in the treatment of endometriosis: impact beyond pain symptoms

被引:11
作者
Archer, David F. [1 ]
Soliman, Ahmed M. [2 ]
Agarwal, Sanjay K. [3 ]
Taylor, Hugh S. [4 ]
机构
[1] Eastern Virginia Med Sch, Dept Obstet & Gynecol, CONRAD Clin Res Ctr, 601 Colley Ave,Suite 241, Norfolk, VA 23507 USA
[2] AbbVie Inc, Hlth Econ & Outcomes Res, N Chicago, IL USA
[3] Univ Calif San Diego, Ctr Endometriosis Res & Treatment, San Diego, CA 92103 USA
[4] Yale Sch Med, Dept Obstet & Gynecol & Reprod Sci, New Haven, CT USA
来源
THERAPEUTIC ADVANCES IN REPRODUCTIVE HEALTH | 2020年 / 14卷
关键词
elagolix; endometriosis; fatigue; phamacoeconomics; quality of life;
D O I
10.1177/2633494120964517
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly recognized. Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that is approved for the management of moderate to severe pain associated with endometriosis. However, the benefits of elagolix extend beyond reducing pain symptoms. This article reviews the non-pain systemic manifestations associated with endometriosis and summarizes the beneficial effects of elagolix on non-pain outcomes. This includes improvements in quality of life, reductions in fatigue and improvements in workplace and household productivity. These results indicate that elagolix provides non-pain benefits in women with endometriosis and improves outcomes that are clinically meaningful to patients.
引用
收藏
页数:12
相关论文
共 50 条
[1]   Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study [J].
Acs, Nandor ;
O'Brien, Chris ;
Jiang, Ping ;
Burke, Joshua ;
Jimenez, Roland ;
Garner, Elizabeth ;
Chwalisz, Kristof .
JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS, 2015, 7 (02) :56-62
[2]   The Systemic Effects of Endometriosis [J].
Alderman, Myles H., III ;
Yoder, Nicole ;
Taylor, Hugh S. .
SEMINARS IN REPRODUCTIVE MEDICINE, 2017, 35 (03) :263-270
[3]  
[Anonymous], 2019, HEALTHMEASURE BRIEF
[4]  
[Anonymous], 2019, ORL EL PRESCR INF
[5]   Systematic review of quality of life measures in patients with endometriosis [J].
Bourdel, Nicolas ;
Chauvet, Pauline ;
Billone, Valentina ;
Douridas, Giannis ;
Fauconnier, Arnaud ;
Gerbaud, Laurent ;
Canis, Michel .
PLOS ONE, 2019, 14 (01)
[6]   Mechanisms of Disease Endometriosis [J].
Bulun, Serdar E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (03) :268-279
[7]   Pathogenesis and pathophysiology of endometriosis [J].
Burney, Richard O. ;
Giudice, Linda C. .
FERTILITY AND STERILITY, 2012, 98 (03) :511-519
[8]   Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study [J].
Carr, Bruce ;
Giudice, Linda ;
Dmowski, W. Paul ;
O'Brien, Chris ;
Jiang, Ping ;
Burke, Joshua ;
Jimenez, Roland ;
Hass, Steven ;
Fuldeore, Mahesh ;
Chwalisz, Kristof .
JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS, 2013, 5 (03) :105-115
[9]   Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density [J].
Carr, Bruce ;
Dmowski, W. Paul ;
O'Brien, Chris ;
Jiang, Ping ;
Burke, Joshua ;
Jimenez, Roland ;
Garner, Elizabeth ;
Chwalisz, Kristof .
REPRODUCTIVE SCIENCES, 2014, 21 (11) :1341-1351
[10]  
Chaman-Ara K, 2017, WORLD CANCER RES J, V4